Claims for Patent: 6,974,681

Summary for Patent: 6,974,681

Title:	Cell culture performance with vanadate
Abstract:	The invention provides methods and compositions for improved in vitro culture of cells that make use of vanadate. The methods enhance cell survival thereby recovery of the polypeptide of interest produced in the cells is increased relative to cells grown without vanadate.
Inventor(s):	McGrew; Jeffrey T (Seattle, WA)
Assignee:		Immunex Corporation (Seattle, WA)
Application Number:	10/226,669
Patent Claims:	1. A method comprising culturing a cell line recombinantly engineered to express a polypeptide of interest, wherein the cell line is cultured in medium comprising an effective amount of vanadate, whereby cell survival is increased and recovery of the secreted polypeptide of interest is increased relative to cells grown without vanadate. 2. The method of claim 1, wherein the recombinantly engineered cell line is a mammalian cell line. 3. The method of claim 2, wherein the mammalian cells are selected from the group consisting of CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, a myeloma cell line, a hybridoma cell line, and W138 cells. 4. The method of claim 3, wherein the recombinantly engineered cell line is grown for at least 20 hours. 5. The method of claim 3, wherein the medium is serum free. 6. The method of claim 3, wherein the medium contains less than about 100 .mu.g/L of IGF-1. 7. The method of claim 6, wherein the medium contains about 25 .mu.g/L of insulin-like growth factor (IGF-1). 8. The method of claim 3, wherein the recombinantly engineered cell line is grown in a proliferative phase in the absence of vanadate and subsequently in an induction phase for recombinant polypeptide production in the presence of vanadate. 9. The method of claim 8, wherein the vanadate is a peroxovanadate. 10. The method of claim 9, wherein the peroxovanadate is selected from the group consisting of monoperoxovanadate (VL) and diperoxovanadate (VL.sub.2). 11. The method of claim 8, wherein the vanadate is sodium orthovanadate. 12. The method of claim 11, wherein the sodium orthovanadate is at a concentration of between about 1 .mu.M to about 50 .mu.M. 13. The method of claim 12, wherein the sodium orthovanadate is at a concentration of above about 10 .mu.M. 14. The method of claim 12, wherein the sodium orthovanadate is at a concentration of above about 20 .mu.M. 15. The method of claim 12, wherein the sodium orthovanadate is at a concentration of about 35 .mu.M. 16. The method of claim 15, wherein the recombinantly engineered cells produce a polypeptide of interest which is selected from the group consisting of a soluble TNF receptor, a soluble IL-4 receptor, a soluble IL-1 type 11 receptor, a soluble flt3 ligand, a soluble CD40 ligand, an erythropoeitin, an antibody, an Fc-fusion polypeptide, a calcitonin, a growth hormone, an insulinotropin, a parathyroid hormone, an interferons, a nerve growth factor, a glucagon, an interleukins, a colony stimulating factor, a glucocerebrosidase, a superoxide dismutase, a tissue plasminogen activator, a Factor VIII, a Factor IX, an apolipoprotein E, an apolipoprotein A-I, a globin, an IL-2 receptor, an IL-2 antagonist, alpha-1 antitrypsin, and an alpha-galactosidase A. 17. The method of claim 16, wherein the cell line is cultured in a bioreactor. 18. The method of claim 17, wherein the cell line is cultured in suspension cultures. 19. The method of claim 17, further comprising collecting the polypeptide of interest. 20. A cell culture comprising a cell line recombinantly engineered to secrete a polypeptide of interest, a culture medium and an effective amount of vanadate sufficient to increase cell viability and to increase recovery of the polypeptide of interest. 21. The cell culture of claim 20, wherein the recombinantly engineered cell line is a mammalian cell line. 22. The cell culture of claim 21, wherein the mammalian cell line is selected from the group consisting of CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, a myeloma cell line, a hybridoma cell line, and W138 cells. 23. The cell culture of claim 22, wherein the recombinantly engineered cell line is grown for at least 20 hours. 24. The cell culture of claim 22, wherein the culture medium is serum free. 25. The cell culture of claim 22, wherein the culture medium contains about 25 .mu.g/L of insulin-like growth factor (IGF-1). 26. The cell culture of claim 22, wherein the culture medium contains from about 25 .mu.g/L to less than about 100 .mu.g/L IGF-1. 27. The cell culture of claim 22, wherein the recombinantly engineered cell line is grown in a proliferative phase in the absence of vanadate and subsequently in an induction phase for recombinant polypeptide production in the presence of vanadate. 28. The cell culture of claim 27, wherein the vanadate is a peroxovanadate. 29. The cell culture of claim 28, wherein the peroxovanadate is selected from the group consisting of monoperoxovanadate (VL) and diperoxovanadate (VL2). 30. The cell culture of claim 27 wherein the vanadate is sodium orthovanadate. 31. The cell culture of claim 30, wherein the sodium orthovanadate is at a concentration of between about 1 .mu.M to about 50 .mu.M. 32. The cell culture of claim 31, wherein the sodium orthovanadate is at a concentration of above about 10 .mu.M. 33. The cell culture of claim 32, wherein the sodium orthovanadate is at a concentration of above about 20 .mu.M. 34. The cell culture of claim 33, wherein the sodium orthovanadate is at a concentration of about 35 .mu.M. 35. The cell culture of claim 34, wherein the recombinantly engineered cells produce a polypeptide of interest which is selected from the group consisting of a soluble TNF receptor, a soluble IL-4 receptor, a soluble IL-1 type II receptor, a soluble flt3 ligand, a soluble CD40 ligand, an erythropoeitin, an antibody, an Fc-fusion polypeptide, a calcitonin, a growth hormone, an insulinotropin, a parathyroid hormone, an interferons, a nerve growth factor, a glucagon, an interleukins, a colony stimulating factor, a glucocerebrosidase, a superoxide dismutase, a tissue plasminogen activator, a Factor VIII, a Factor IX, an apolipoprotein E, an apolipoprotein A-I, a globin, an IL-2 receptor, an IL-2 antagonist, alpha-1 antitrypsin, and an alpha-galactosidase A. 36. The cell culture of claim 35, wherein the cell line is cultured in bioreactors. 37. The cell culture of claim 36, further comprising collecting the polypeptide of interest. 38. The cell culture of claim 36, wherein the cell line is grown in suspension.

Details for Patent 6,974,681

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2039-03-29